140 related articles for article (PubMed ID: 32075421)
1. The Carter Lab at NIH: A Model of Inclusive Excellence in Biomedical Research.
Owens RA
Hum Gene Ther; 2020 May; 31(9-10):512-517. PubMed ID: 32075421
[TBL] [Abstract][Full Text] [Related]
2. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.
Rutledge EA; Halbert CL; Russell DW
J Virol; 1998 Jan; 72(1):309-19. PubMed ID: 9420229
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy for Cystic Fibrosis Paved the Way for the Use of Adeno-Associated Virus in Gene Therapy.
Guggino WB; Cebotaru L
Hum Gene Ther; 2020 May; 31(9-10):538-541. PubMed ID: 32283956
[TBL] [Abstract][Full Text] [Related]
4. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors.
Halbert CL; Allen JM; Miller AD
J Virol; 2001 Jul; 75(14):6615-24. PubMed ID: 11413329
[TBL] [Abstract][Full Text] [Related]
5. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
[TBL] [Abstract][Full Text] [Related]
6. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.
Shi W; Arnold GS; Bartlett JS
Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765
[TBL] [Abstract][Full Text] [Related]
7. Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy.
Flotte TR
Mol Ther; 2013 Nov; 21(11):1976-81. PubMed ID: 24201212
[No Abstract] [Full Text] [Related]
8. Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences.
Aurnhammer C; Haase M; Muether N; Hausl M; Rauschhuber C; Huber I; Nitschko H; Busch U; Sing A; Ehrhardt A; Baiker A
Hum Gene Ther Methods; 2012 Feb; 23(1):18-28. PubMed ID: 22428977
[TBL] [Abstract][Full Text] [Related]
9. Manufacturing of adeno-associated viruses, for example: AAV2.
Chen H
Methods Mol Biol; 2011; 737():235-46. PubMed ID: 21590400
[TBL] [Abstract][Full Text] [Related]
10. Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19.
Heister T; Heid I; Ackermann M; Fraefel C
J Virol; 2002 Jul; 76(14):7163-73. PubMed ID: 12072516
[TBL] [Abstract][Full Text] [Related]
11. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
Janelidze S; Nordström U; Kügler S; Brundin P
J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
[TBL] [Abstract][Full Text] [Related]
12. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.
Lotfinia M; Abdollahpour-Alitappeh M; Hatami B; Zali MR; Karimipoor M
Clin Exp Med; 2019 Aug; 19(3):289-298. PubMed ID: 31054018
[TBL] [Abstract][Full Text] [Related]
13. Bat adeno-associated viruses as gene therapy vectors with the potential to evade human neutralizing antibodies.
Li Y; Li J; Liu Y; Shi Z; Liu H; Wei Y; Yang L
Gene Ther; 2019 Jun; 26(6):264-276. PubMed ID: 31110296
[TBL] [Abstract][Full Text] [Related]
14. Clinical gene therapy using recombinant adeno-associated virus vectors.
Mueller C; Flotte TR
Gene Ther; 2008 Jun; 15(11):858-63. PubMed ID: 18418415
[TBL] [Abstract][Full Text] [Related]
15. Continuous Collection of Adeno-Associated Virus from Producer Cell Medium Significantly Increases Total Viral Yield.
Benskey MJ; Sandoval IM; Manfredsson FP
Hum Gene Ther Methods; 2016 Feb; 27(1):32-45. PubMed ID: 26863210
[TBL] [Abstract][Full Text] [Related]
16. Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy.
Liu Y; Siriwon N; Rohrs JA; Wang P
Curr Pharm Des; 2015; 21(22):3248-56. PubMed ID: 26027561
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Capsid Proteins Impact Transduction Efficiency of Haploid Adeno-Associated Virus Vectors.
Chai Z; Zhang X; Dobbins AL; Frost EA; Samulski RJ; Li C
Viruses; 2019 Dec; 11(12):. PubMed ID: 31835440
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated virus vector as a platform for gene therapy delivery.
Wang D; Tai PWL; Gao G
Nat Rev Drug Discov; 2019 May; 18(5):358-378. PubMed ID: 30710128
[TBL] [Abstract][Full Text] [Related]
19. Insertional mutagenesis at positions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism.
Shi X; Fang G; Shi W; Bartlett JS
Hum Gene Ther; 2006 Mar; 17(3):353-61. PubMed ID: 16544984
[TBL] [Abstract][Full Text] [Related]
20. In vivo model of adeno-associated virus vector persistence and rescue.
Afione SA; Conrad CK; Kearns WG; Chunduru S; Adams R; Reynolds TC; Guggino WB; Cutting GR; Carter BJ; Flotte TR
J Virol; 1996 May; 70(5):3235-41. PubMed ID: 8627804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
